We retrospectively reviewed 126 patients (pts) who received VEN...These data also showed that ASXL1 (31.6%) and NOTCH1 (31.6%) (both p=0.016) mutations were detected only in the PD group (mVAF: ASXL1 19.3%; NOTCH1 52.9%)...Our clinical sequencing data showed that SF3B1 mutations significantly co-occurred with BCL2 G101V mutations (57.1% in BCL2 G101V vs. 8.33% in those without, p=0.035, mVAF 27.8 vs 0.3%)....We retrospectively analyzed gene mutations among venetoclax treated pts and showed that ASXL1 and NOTCH1 were frequently mutated in the resistant cohort. We also evaluated BCL2 G101V mutations using ddPCR and demonstrated that SF3B1 gene mutations were highly co-mutated with BCL-2.